Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW Clarifies When Generic Drug Mergers Must Be Reviewed by Antitrust Regulator
November 5, 2025
- LDP Project Team Urges Economic Measures Reflecting Price Pressures
November 4, 2025
- Former Flagship Brands among 506 Drugs Set for Delisting
November 4, 2025
- Anticoagulants and Other Drugs under PMDA Safety Review
November 4, 2025
- Health Minister Vows to Balance Public Burden, Innovation, and Supply in FY2026 Revision
October 31, 2025
- LDP Eyes Support for Drug Wholesalers in Upcoming Economic Package
October 31, 2025
- Shionogi/Sage’s Zurzuvae Clears MHLW Panel, Label Wording on Combo Use under Review
October 31, 2025
- Japan Mulls Full Overhaul of LLP Rule under FY2026 Drug Pricing Reform
October 30, 2025
- Data Error Delayed Japan Review of Subcutaneous Rybrevant; Approval Still Expected This Year
October 30, 2025
- Japan to Delist 506 Drugs from NHI Price List, Including Category A Products and LLPs
October 30, 2025
- Exclude High-Price-Gap Products from Unprofitable Drug Re-Pricing: Chuikyo
October 30, 2025
- FIRM Urges Continued Premiums for Conditionally Approved Regenerative Medicines
October 30, 2025
- Japan Eyes Review of Generic Price Bands, Brand-Based Revisions for Tier A Products
October 30, 2025
- Japan PM Warns of Overreliance on China for Pharmaceutical Ingredients
October 29, 2025
- Public-Private WG’s Discussion Summary Focuses on Drug Pricing, Raises MFN Risk
October 29, 2025
- Japan Finalizes Designation of 762 “Supply-Ensured Medicines”
October 28, 2025
- Takaichi Vows Cross-Party Talks on Social Security Reform
October 27, 2025
- Chuikyo Members Call for Revising Clozapine Fee Criteria to “Hospital-Based” Calculation
October 27, 2025
- Japan Panel OKs PCV20 as Routine Pneumococcal Shot for Elderly
October 27, 2025
- Japan Panel Backs NIP Use of High-Dose Flu Shot; Talks Continue on RSV Prevention
October 27, 2025
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…